NCT05795192View on ClinicalTrials.gov

SB17170 Phase1 Trial in Healthy Volunteer

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

May 24, 2023

Primary Completion Date

February 29, 2024

Study Completion Date

March 15, 2024

Conditions
Safety IssuesTolerabilityPharmacokineticsPharmacodynamics
Interventions
DRUG

SB17170

Taking SB17170 orally once a day

DRUG

Placebo

Taking Placebo orally once a day

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

SPARK Biopharma
All Listed Sponsors
lead

SPARK Biopharma

INDUSTRY